Copyright © 2024 Research Nester. All Rights Reserved
Lymphangioleiomyomatosis (LAM) Market size was over USD 128.91 million in 2023 and is anticipated to cross USD 237.13 million by 2036, growing at more than 4.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of lymphangioleiomyomatosis is estimated at USD 133.86 million.
Lymphangioleiomyomatosis (LAM) is a lethargic, progressive growth of smooth muscle cells all through the lungs, pulmonary blood vessels, lymphatics, and pleurae, leading to alteration of lung architecture, cystic emphysema, and progressive worsening of lung function. LAM is predominant in women, usually affecting those between 20 and 40 years. It is caused by mutations in the TSC1 or TSC2 genes, that are vital for the production of a protein known as hamartin and tuberin, responsible for destroying the tumors by preventing cells from growing and dividing in an uncontrolled way. Diagnosis is suspected based on symptoms and chest x-ray results and is confirmed by high-resolution CT, but the illness is slowly progressive and might often lead to respiratory failure and death in the future. Treatment might include consuming sirolimus or lung transplantation.
An increase in the occurrence of target diseases and a rise in the number of lifestyle-related disorders are the key factors that are driving the growth of the lymphangioleiomyomatosis (LAM) market.
Furthermore, initiatives taken by numerous government and private organizations to spread alertness for the disease, rise in disposable income and surge in healthcare facilities in developing nations, novel R&D initiatives to produce medications, technological advancements, and investments by major players are estimated to drive the lymphangioleiomyomatosis (LAM) market growth in the forecast period.
Challenges
Stringent government regulations in certain nations, lack of awareness, slow detection of the disease, and high costs involved in the treatments might also contribute as the growth constraints for the overall lymphangioleiomyomatosis (LAM) market.
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
4.8% |
|
Base Year Market Size (2023) |
USD 128.91 million |
|
Forecast Year Market Size (2036) |
USD 237.13 million |
|
Regional Scope |
|
The lymphangioleiomyomatosis (LAM) market is segmented by type, therapy type, treatment, drugs, route of administration, end-users, distribution channel, and region. Among distribution channel segmentation, the hospital pharmacies segment is anticipated to grow significantly during the forecast period on account of growing numbers for registered lung disease patients worldwide, rising awareness for chronic lung diseases, and R&D initiatives resulting in advanced medications and drugs to cure the illness.
Our in-depth analysis of the global market includes the following segments:
By Type |
|
By Therapy Type |
|
|
By Treatment |
|
By Drugs |
|
By Route Of Administration |
|
By End-Users |
|
By Distribution Channel |
|
Geographically, the lymphangioleiomyomatosis (LAM) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America industry is likely to account for largest revenue share by 2036, attributed to factors such as high healthcare spending, a high rate of adoption of technologies, a rise in the prevalence of lifestyle-related disorders, and a promising pipeline. Further, the ease of availability of lymphangioleiomyomatosis therapies, rise in R&D concerning lymphangioleiomyomatosis, and the availability of reimbursements are also contributing towards the regional growth.
According to the U.S. Department of Health and Human Services, the number of women in the U.S. who have been diagnosed with lung disease is increasing.
The European region is anticipated to hold the second-largest market share in the l lymphangioleiomyomatosis (LAM) market after North America on account of rising government spending related to healthcare facilities in the region.
Asia-Pacific is estimated to grow at the fastest rate during the forecast period. Factors such as growth in the incidence of lymphangioleiomyomatosis disorders, lung infections & surgeries, increased menopausal female populations, upsurge in healthcare expenditure, penetration of leading players, budding population, and a rise in disposable income, are projected to propel the growth in the Asia-Pacific region.
Latin America and the Middle East and Africa are estimated to experience scalable heights in the foreseeable future on account of efforts made by the governments of these regions to promote the use of medications and spread the awareness related to health disorders.
January 7, 2020: AI Therapeutics, a clinical-stage biopharmaceutical company, announced substantial progress on two of their programs - LAM-001, world’s first inhaled formulation of rapamycin that would be studied in clinical trials and LAM-004, which has finished a Phase 1 trial in patients having facial angiofibroma.
January 16, 2020: AI Therapeutics announced that their LAM-002 has received Fast Track status and Orphan Drug Designation from the U.S. FDA for Pivotal Trial Design of the treatment of follicular lymphoma.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?